Huang C I, Taki T, Higashiyama M, Kohno N, Miyake M
Department of Thoracic Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Kitaku, Osaka, Japan.
Br J Cancer. 2000 Jan;82(2):374-80. doi: 10.1054/bjoc.1999.0929.
An immunohistochemical analysis for p16 protein was performed in 171 patients with non-small-cell lung cancer (NSCLC). Sixty-two carcinomas (36.3%) were classified as p16-negative. p16-negative tumours in squamous cell carcinomas (SCCs) were significantly more than those in adenocarcinomas (P = 0.039). There was no significant difference in survival according to tumour p16 status in patients with NSCLCs or in patients with adenocarcinomas. In contrast, of patients with SCCs, the 5-year survival rate of patients with p16-negative tumours was significantly lower than those with p16-positive tumours (P = 0.001). Especially, the survival of patients with p16-negative tumours was significantly worse than that of patients with p16-positive tumours in the early stage of the SCC, e.g. stage I (P = 0.005). Multivariate analysis showed that p16 status and nodal status were significant prognostic factors for the survival of patients with SCCs of the lung (P = 0.024 and P = 0.008 respectively). In conclusion, our study showed that alteration of p16 was one of the significant factors of a poor prognosis in SCCs of the lung, and that p16 might play an important role in some SCCs of the lung due to its high prevalence and prognostic value.
对171例非小细胞肺癌（NSCLC）患者进行了p16蛋白的免疫组化分析。62例癌（36.3%）被分类为p16阴性。鳞状细胞癌（SCC）中p16阴性肿瘤显著多于腺癌（P = 0.039）。NSCLC患者或腺癌患者中，根据肿瘤p16状态，生存率无显著差异。相比之下，在SCC患者中，p16阴性肿瘤患者的5年生存率显著低于p16阳性肿瘤患者（P = 0.001）。特别是，在SCC早期，如I期，p16阴性肿瘤患者的生存率显著低于p16阳性肿瘤患者（P = 0.005）。多因素分析显示，p16状态和淋巴结状态是肺SCC患者生存的重要预后因素（分别为P = 0.024和P = 0.008）。总之，我们的研究表明，p16改变是肺SCC预后不良的重要因素之一，并且由于其高发生率和预后价值，p16可能在某些肺SCC中起重要作用。
